Gene therapies, delivered via adeno-associated viruses (AAVs), have immense potential, but face challenges in crossing the blood-brain barrier, which hinders treatment for brain disorders.
While AAVs can deliver genes effectively, their inability to penetrate the blood-brain barrier remains a significant obstacle, impacting the development of vital therapies for neurological diseases.
Research led by Deverman at the Broad Institute aims to engineer a modified AAV capable of traversing the blood-brain barrier, opening pathways to treat brain disorders.
The blood-brain barrier serves as a critical protector, filtering vital substances but additionally prevents potentially life-saving gene therapies from reaching targeted areas in the brain.
#gene-therapy #adeno-associated-viruses #blood-brain-barrier #neurological-disorders #biomedical-research
Collection
[
|
...
]